AstraZeneca PLC (NASDAQ: AZN) Expected to Post Earnings of $ 0.59 Per Share After Q1 2021


AstraZeneca PLC (NASDAQ: AZN) – SVB Leerink investment analysts lowered their estimates of first quarter 2021 earnings per share (EPS) for AstraZeneca shares in a report released on Thursday, April 29. SVB Leerink analyst A. Berens now expects the company to post earnings of $ 0.59 per share for the quarter, down from their previous estimate of $ 0.60. SVB Leerink currently has an “Outperformance” rating and a target share price of $ 63.00. SVB Leerink also released estimates for AstraZeneca’s second quarter 2021 profit at $ 0.58, third quarter 2021 profit at $ 0.61, year 2022 profit at $ 3.00 and profit for fiscal year 2025 at $ 4.23.

A number of other brokerages have also recently commented on AZN. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” note on AstraZeneca shares in a report on Thursday, March 18. Societe Generale reissued a “buy” note on AstraZeneca shares in a research note on Tuesday March 23. In a research report on Wednesday March 3, UBS Group upgraded AstraZeneca shares from a “neutral” rating to a “buy” rating. Jefferies Financial Group upgraded AstraZeneca shares from a “hold” rating to a “buy” rating in a research report on Monday, March 22. Finally, Berenberg Bank reiterated a “buy” note on AstraZeneca shares in a research report on Tuesday, March 9. One stock research analyst rated the stock with a sell rating, three rated the stock as sustaining, and eleven rated the stock with a buy rating. AstraZeneca currently has a consensus rating of “Buy” and a consensus target price of $ 83.40.

Actions of AZN open for $ 51.37 on Fridays. AstraZeneca has a one-year low of $ 46.48 and a one-year high of $ 64.94. The company has a current ratio of 0.96, a quick ratio of 0.76 and a debt ratio of 1.34. The company’s 50-day average mobile price is $ 50.21 and its 200-day average mobile price is $ 50.88. The company has a market cap of $ 134.83 billion, a price / earnings ratio of 53.51, a PEG ratio of 1.18 and a beta of 0.55. AstraZeneca (NASDAQ: AZN) last released its results on Wednesday, February 10. The company reported EPS of $ 0.54 for the quarter, missing analyst consensus estimates of $ 0.68 from ($ 0.14). The company posted revenue of $ 7.41 billion in the quarter, compared to analysts’ expectations of $ 6.98 billion. AstraZeneca recorded a return on equity of 37.23% and a net margin of 9.65%.

The company also recently declared a semi-annual dividend, which was paid on Monday, March 29. Investors of record on Friday February 26 received a dividend of $ 0.95. This represents a yield of 2.7%. The ex-dividend date was Thursday, February 25. This is an increase from AstraZeneca’s previous semi-annual dividend of $ 0.45. AstraZeneca’s dividend payout ratio (DPR) is currently 106.29%.

A number of hedge funds have recently bought and sold shares of AZN. BlackRock Inc. increased its stake in AstraZeneca by 73.7% in the 4th quarter. BlackRock Inc. now owns 12,062,631 shares of the company valued at $ 603,010,000 after purchasing an additional 5,116,892 shares during the period. Voloridge Investment Management LLC acquired a new position in AstraZeneca during the 4th quarter valued at approximately $ 154,257,000. Price T Rowe Associates Inc. MD increased its position in AstraZeneca by 18.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,596,691 shares of the company valued at $ 929,649,000 after purchasing an additional 2,946,561 shares during the period. Avidity Partners Management LP acquired a new position in AstraZeneca during the 4th quarter valued at approximately $ 114,977,000. Finally, First Trust Advisors LP acquired a new position in AstraZeneca during the 4th quarter valued at approximately $ 54,011,000. 15.57% of the stock is currently held by institutional investors.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the fields of oncology, cardiovascular, kidney and metabolism, respiration, infections, neuroscience and gastroenterology worldwide. Products marketed by the company include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex / Cosudex and others for oncological diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin and others for cardiovascular, renal and metabolic diseases; and Symbicort, Pulmicort, Fasenra, Daliresp / Daxas, Duaklir, Tudorza / Eklira, Bevespi, Breztri, Anifrolumab and others for respiratory and immunological diseases.

See also: Percentage of winners

History and revenue estimates for AstraZeneca (NASDAQ: AZN)

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured article: What is the Stochastic Momentum Index (SMI)?

7 stocks Cathie Wood buys and you should too

If you are an investor who likes to go with the ‘hot hand’ then they don’t get much hotter than Cathie Wood. The founder and CEO of ARK Investment Management generated returns of over 100% in her firm’s five exchange-traded funds (ETFs) in 2020.

The names of its funds feature some of the hottest emerging growth trends in the market: financial technology (fintech), the genomic revolution, innovation, autonomous / robotics technology and the next generation internet.

As you might expect, these funds contain some of the hottest growth stocks of the past year. And as a result of the technology sale, Wood is not backing down. In fact, it doubles its strategy. It may not be exactly a matter of gluttony when others are afraid; maybe more like being prepared while others are distracted.

But the other thing about Wood’s picks is that a lot of them aren’t obscure names. These are companies that were among the hottest names in 2020. Wood just thinks they still have room to operate. And that’s one of the reasons why you should consider incorporating them into your portfolio.

In this special presentation, we present to you only seven of the stocks that Cathie Wood is buying or has bought recently. We have attempted to select at least one stock from each of the ARK ETFs. As with any investment decision, it is important that you do your own research before making a decision.

See “7 stocks that Cathie Wood buys and you should too”.

Leave A Reply

Your email address will not be published.